Intercept Pharmaceuticals, Inc.
$5.1M 13,236 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Actelion Pharmaceuticals US, Inc.
Actelion Pharmaceuticals US, Inc. reported $5,166,141.64 across General Payments, Research, and Ownership to 31,311 physicians and teaching hospitals across 31,315 transactions.
- $5.2M
- All-tracks total
- 31,315
- Transactions
- 31,311
- Recipients
- +$101.9K
- General Payments vs PY2023
Actelion Pharmaceuticals US, Inc. reported $5,166,141.64 across all CMS Open Payments tracks (General + Research + Ownership) to 31,311 physicians and teaching hospitals in Program Year 2024 - ranking #268 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $5,004,722.78, averaging $164.99 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer actelion-pharmaceuticals-us-inc Actelion Pharmaceuticals US, Inc.
$5.2M · #268/1,925 · 0.0% industry · PY2024
- TOT $5.2M
- RANK #268
- SHARE 0.0%
- TXN 31,315
- RCP 31,311
- CAT 7
- GEN $5.0M
- ΔGEN +$101.9K
- TOP1 7.1%
- PY 2024
Volume peers
Nearest volume peer: Intercept Pharmaceuticals, Inc. ($5.1M)
Actelion Pharmaceuticals US, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Actelion Pharmaceuticals US, Inc.'s CMS-reported General Payments increased by $101.9K (+2.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ACTELION PHARMACEUTICALS US, INC.PY2023: ACTELION PHARMACEUTICALS US, INC.PY2024: Actelion Pharmaceuticals US, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $4,902,789.78
- PY2024
- $5,004,722.78
What the Data Shows for Actelion Pharmaceuticals US, Inc.
Averaging $164.97 per transaction and $164.99 per recipient, Actelion Pharmaceuticals US, Inc.'s Program Year 2024 total comes to $5,166,141.64 across 31,315 transactions and 31,311 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #268 of 1,925 companies, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
Of the 7 general-payment categories charted below, "Compensation for Services Other Than Consulting" is the largest at $2.4M across 816 transactions, 47.4% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Compensation for Services Other Than Consulting" leads Actelion Pharmaceuticals US, Inc.'s 7-category general-payment breakdown at $2.4M, 47.4% of the reported total.
Actelion Pharmaceuticals US, Inc. reports 7 general-payment categories - the top three are Compensation for Services Other Than Consulting (47.4%), Food and Beverage (17.9%), and Consulting Fee (14.7%). The remaining 4 categories make up 20.0% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Actelion Pharmaceuticals US, Inc. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $2.4M | 816 | 47.4% |
| Food and Beverage | $898.2K | 27,893 | 17.9% |
| Consulting Fee | $733.2K | 211 | 14.7% |
| Grant | $420.0K | 4 | 8.4% |
| Travel and Lodging | $385.6K | 1,311 | 7.7% |
| Space Rental or Facility Fees | $106.6K | 32 | 2.1% |
| Education | $88.8K | 1,044 | 1.8% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $803,201.96 (16.0%) of $5,004,722.78 in this company's General Payments records across 11,628 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Actelion Pharmaceuticals US, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Temple University Hospital
$355,000.00 across 2 reported transactions
- 2
John Joseph Ryan
$128,960.24 across 137 reported transactions
- 3
Hunter C Champion
$112,856.96 across 104 reported transactions
- 4
Omar a Minai
$107,123.60 across 114 reported transactions
- 5
John W Mcconnell
$99,261.16 across 96 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Actelion Pharmaceuticals US, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Actelion Pharmaceuticals US, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Actelion Pharmaceuticals US, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
SK Life Science, Inc.
$5.1M 20,538 recipients
Compare payment profiles
Pristine Surgical LLC
$5.1M 5 recipients
Compare payment profiles
BioXcel Therapeutics, Inc.
$5.2M 532 recipients
Compare payment profiles
Mitsubishi Tanabe Pharma America, Inc.
$5.2M 3,683 recipients
Compare payment profiles
BrainScope Company, Inc.
$5.1M 25 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.